DEC 1 0 2003 K 033586
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
SYNERON MEDICAL Ltd. AURORA DS
This summary of safety and effectiveness information is being submitted in
accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.
Submitter: | Syneron Medical Ltd., Appolo Bld.,
Industrial Zone
Yoqneam Illit, Israel
Tel. +972.4.909-7424, Fax +972.4. 909-7417
Name of the Device: Aurora DS
Predicate Devices: This is a Special 510(k) for the Aurora
DS that was cleared under K031988.
Device Description: The Aurora DS is a device that is used
for non-invasive hair removal. The
Aurora DS treatment is based on a
principle of selective thermolysis.
According to this principle, parameters
of optical and RF energy (spectrum,
exposure duration and energy density)
are chosen (and optimized) to selectively
damage (destroy) hair and follicle
without damaging the surrounding
tissues.
The Aurora DS is intended for use in dermatology for non invasive hair removal.
The modifications to the Aurora DS do not affect the intended use or alter the
fundamental scientific technology of the device. The only device modification an
increase in the light energy output. There are no labeling changes that affect the
intended use of the device. The device modifications raise no new issues of safety or
effectiveness.
6 November 2003 RN wu C \W Ww |
Date Dr, Amir Waldman
Director, Regulatory affairs
Syneron Medical Ltd.

a
f DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
LE
vena Food and Drug Administration
9200 Corporate Boulevard
DEC 1 0 2003 Rockville MD 20850
Dr. Amir Waldman
Director, Regulatory Affairs
Syneron Medical Ltd.
Sultam Industrial Park
P.O.B. 550 Yokneam Elite
20692 Israel
Re: K033586
Trade/Device Name: Aurora DS
Regulation Number: 21 CFR 878.4810; 21 CFR 878.4400
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in
dermatology; Electrosurgical cutting and coagulation device and
accessories
Regulatory Class: II
Product Code: GEX, GEI
Dated: November 6, 2003
Received: November 14, 2003
Dear Dr. Waldman:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Pood, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class IT] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination docs not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencics. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Dr. Amir Waldman
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled.
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain, htm!

Sincerely yours,

Tham C. Pavort
fl celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Iealth
Enclosure

510(k) Number , Kk 03359f .
Device Name ___ Aurora DS .
Indications For Use: (separate page)
The Aurora DS is indicated for non-invasive hair removal.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use VA OR Over The Counter Use
(Per 21 CFR 801.109)
(Optional Format 1-2-96)

Division Sign-Off) .

Division of General, Restorative

and Neurologic! Devices

§10(k) Number __K0335% .

